Amlodipine/valsartan/rosuvastatin (CJ-30060) vs OLOMAX

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Angiotensin II receptor / Calcium channel / HMG-CoA reductase · full Hypertension pipeline

Amlodipine/valsartan/rosuvastatin (CJ-30060)

Developed by HK inno.N Corporation

Phase 3 in Hypertensionsmall molecule (combination)
Partial signal

NCT03536598 · Phase 3 · completed

The trial randomly assigned 203 participants and used quadruple blinding with two active comparator groups. Its primary endpoints were changes in LDL-C and sitting systolic blood pressure at 8 weeks, but no results or statistical comparisons are posted, so the primary endpoint cannot be judged as met or missed.

No aligned efficacy figure on record for this race.

OLOMAX

Marketed by Daewoong Pharmaceutical

small molecule (combination)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAmlodipine/​valsartan/​rosuvastatin (CJ-30060)OLOMAX
Seated SBP, change—Not posted · NCT03536598—Not reported
24-hour ambulatory SBP, change—Not posted · NCT03536598—Not reported
Seated DBP, change—Not posted · NCT03536598—Not reported

Seated SBP, change

Amlodipine/​valsartan/​rosuvastatin (CJ-30060)
—Not posted · NCT03536598
OLOMAX
—Not reported

24-hour ambulatory SBP, change

Amlodipine/​valsartan/​rosuvastatin (CJ-30060)
—Not posted · NCT03536598
OLOMAX
—Not reported

Seated DBP, change

Amlodipine/​valsartan/​rosuvastatin (CJ-30060)
—Not posted · NCT03536598
OLOMAX
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Amlodipine/valsartan/rosuvastatin (CJ-30060): no structured comparison results are available for Hypertension.

OLOMAX: no structured comparison results are available for Hypertension.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amlodipine/valsartan/rosuvastatin (CJ-30060)'s landscape · OLOMAX's landscape